Tuesday 20 / January / 2026
Muscat: The Royal Hospital has successfully localized advanced molecular tests for colorectal cancer, marking a major milestone in cancer diagnostics in the Sultanate of Oman.
The newly introduced tests include KRAS, NRAS, and BRAF molecular analyses, which are essential for the accurate diagnosis and targeted treatment of colorectal cancer. The tests are being conducted by the Medical Laboratories Department, in collaboration with the Histopathology and Cytology Section, and are being performed locally for the first time after previously being outsourced abroad with waiting periods exceeding three weeks.
This achievement represents a qualitative leap in precision oncology, as the molecular tests can now be completed within one working day, significantly reducing turnaround time. The development enables earlier initiation of targeted therapies, improves clinical decision-making, and enhances the overall quality of care provided to cancer patients.
The advancement aligns with the Ministry of Health’s efforts to expand specialized diagnostic services and strengthen precision medicine, in line with the objectives of Oman Vision 2040, which focuses on localizing advanced medical technologies and building a sustainable, innovation-driven healthcare system.
Dr. Mohammed Al-Masqari, Head of the Histopathology and Cytology Section at the Medical Laboratories Department of the Royal Hospital, said that localizing these molecular tests represents a strategic step in supporting the national cancer treatment framework. He noted that the rapid availability of test results allows physicians to make timely and accurate treatment decisions, ultimately improving the patient’s treatment journey.
He added that the achievement reflects the high technical readiness of medical laboratories and the competence of national healthcare professionals, affirming continued efforts to introduce additional advanced specialized tests in accordance with the highest international standards.
